Chimeric Human Adenoviruses for Cancer Gene Therapy
Author Information
Author(s): Ranki Tuuli, Hemminki Akseli
Primary Institution: University of Helsinki
Hypothesis
Can serotype chimeric adenoviruses enhance the efficacy of cancer gene therapy?
Conclusion
Serotype chimerism may improve the effectiveness of adenoviral vectors in targeting cancer cells while reducing liver toxicity.
Supporting Evidence
- Chimeric adenoviruses can bypass pre-existing immunity in patients.
- Clinical trials showed objective evidence of antitumor activity in 61% to 67% of patients treated.
- Genetic modifications can enhance the delivery of therapeutic agents to cancer cells.
Takeaway
This study looks at using special types of viruses to help treat cancer by making them better at finding and attacking cancer cells without hurting healthy ones.
Methodology
The review discusses various genetic modifications of adenoviruses to enhance their targeting and efficacy in cancer therapy.
Potential Biases
Potential biases in the interpretation of preclinical results and their applicability to human trials.
Limitations
The study primarily focuses on preclinical data and may not fully represent human responses.
Participant Demographics
Patients with various cancer types and advanced solid tumors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website